Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 6/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | UGT2B7 | P16662 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30467247 | 1.00 | CHRNB4 (0.39) | CHRNB4CHRNA3CHRNB2CHRNA4UGT2B7 | |
| SCHEMBL7278396 | 0.94 | SLC6A2 (0.36) | CHRNB4CHRNA3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18194977 | 0.94 | SLC6A2 (0.36) | CHRNB4CHRNA3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28185803 | 0.93 | CHRNB4 (0.35) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL29174518 | 0.83 | CHRNB4 (0.39) | CHRNB4CHRNA3CHRNB2CHRNA4SLC6A2 | |
| SCHEMBL17286013 | 0.83 | CHRNB4 (0.39) | CHRNB4CHRNA3CHRNB2CHRNA4SLC6A2 | |
| SCHEMBL29174517 | 0.83 | CHRNB4 (0.39) | CHRNB4CHRNA3CHRNB2CHRNA4SLC6A2 | |
| SCHEMBL29300216 | 0.82 | CHRNB4 (0.38) | CHRNB4CHRNA3CHRNB2CHRNA4SLC6A2 | |
| SCHEMBL25984818 | 0.80 | CHRNB4 (0.34) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL16902661 | 0.79 | CHRNB4 (0.36) | CHRNB4CHRNA3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107427758-A | Utilize the separation of ion liquid solvent | 切弗朗菲利浦化学公司 | 2017-12-01 | — | — | CN | claimed |
| CN-109844069-A | Utilize isobutane alkylation oil plant amylene | 雪佛龙美国公司 | 2019-06-04 | — | — | CN | disclosed |
| CN-109642165-A | Integrated coalescing system for separating liquid hydrocarbons from dispersed ionic liquid | 雪佛龙美国公司 | 2019-04-16 | — | — | CN | disclosed |
| CN-108982403-A | Integrated system and method for online monitoring of chemical concentration in ionic liquid | 雪佛龙美国公司 | 2018-12-11 | — | — | CN | disclosed |
| CN-108473880-A | Regeneration of acidic ionic liquid without adding hydrogenation catalyst | 雪佛龙美国公司 | 2018-08-31 | — | — | CN | disclosed |
| CN-108014660-A | It is continuously injected into the integrated system of a small amount of immiscible liquids | 雪佛龙美国公司 | 2018-05-11 | — | — | CN | disclosed |
| CN-107427758-A | Utilize the separation of ion liquid solvent | 切弗朗菲利浦化学公司 | 2017-12-01 | — | — | CN | disclosed |
| US-8623881-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2014-01-07 | — | — | US | disclosed |
| US-8492389-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2013-07-23 | — | — | US | disclosed |
| US-8138195-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100168139-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-07-01 | — | — | US | disclosed |
| US-20100152211-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
| WO-2000073269-A2 | NICOTINE RECEPTOR LIGANDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152211-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | CHRNB4 3838/4885CHRNA3 3851/4885CHRNB2 3729/4885 |
| US-20100168139-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | CHRNB4 3838/4885CHRNA3 3851/4885CHRNB2 3729/4885 |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | CHRNB4 4532/4885CHRNA3 4412/4885CHRNB2 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.